Abstract
CD73, also known as ecto-5’-nucleotidase (eN, NT5E, EC3.13.5), is the ratelimiting enzyme for adenosine generation and is expressed on multiple cells. Its expression is significantly influenced by hypoxia and inflammatory factors. During inflammation, CD73 protects endothelial barrier function and inhibits leukocyte trafficking. CD73 also promotes M2 macrophages (anti-inflammatory phenotype). In addition, CD73 is expressed on Treg cells and mediates immune suppression through adenosine. CD73 serves as an essential regulator for the immunity and inflammation. Its expression is related to many diseases, such as autoimmune diseases, ischemia-reperfusion injuries, arterial calcifications, and atherosclerosis. CD73 is overexpressed in many cancers. Its expression is positively associated with tumor growth, metastasis, angiogenesis, poor prognosis and resistance to chemotherapy. Thus, CD73 may be used for prognostic indicator and therapeutic target in diseases such as cancers.
Keywords: CD73, ecto-5'-nucleotidase, cancer, immunity, inflammation, disease.
Current Medicinal Chemistry
Title:Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Volume: 25 Issue: 19
Author(s): Jiayin Yang, Xiaohong Liao, Jerry Yu and Ping Zhou*
Affiliation:
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032,China
Keywords: CD73, ecto-5'-nucleotidase, cancer, immunity, inflammation, disease.
Abstract: CD73, also known as ecto-5’-nucleotidase (eN, NT5E, EC3.13.5), is the ratelimiting enzyme for adenosine generation and is expressed on multiple cells. Its expression is significantly influenced by hypoxia and inflammatory factors. During inflammation, CD73 protects endothelial barrier function and inhibits leukocyte trafficking. CD73 also promotes M2 macrophages (anti-inflammatory phenotype). In addition, CD73 is expressed on Treg cells and mediates immune suppression through adenosine. CD73 serves as an essential regulator for the immunity and inflammation. Its expression is related to many diseases, such as autoimmune diseases, ischemia-reperfusion injuries, arterial calcifications, and atherosclerosis. CD73 is overexpressed in many cancers. Its expression is positively associated with tumor growth, metastasis, angiogenesis, poor prognosis and resistance to chemotherapy. Thus, CD73 may be used for prognostic indicator and therapeutic target in diseases such as cancers.
Export Options
About this article
Cite this article as:
Yang Jiayin, Liao Xiaohong, Yu Jerry and Zhou Ping *, Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target, Current Medicinal Chemistry 2018; 25 (19) . https://dx.doi.org/10.2174/0929867325666180117101114
DOI https://dx.doi.org/10.2174/0929867325666180117101114 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetic Cardiomyopathy and Oxidative Stress: Role of Antioxidants
Cardiovascular & Hematological Agents in Medicinal Chemistry The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design Subject Index To Volume 5
Inflammation & Allergy - Drug Targets (Discontinued) Targeted Gene Deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis and Preserves Cardiac Function by Stabilizing Hypoxia Inducible Factor 1 Alpha Following Myocardial Infarction
Current Pharmaceutical Design Is Nitric Oxide Assuming a Janus-Face in The Central Nervous System?
Current Medicinal Chemistry An Introduction to the Nutrition and Metabolism of Choline
Central Nervous System Agents in Medicinal Chemistry Neuritin, A Neurotrophic Factor in Nervous System Physiology
Current Medicinal Chemistry Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Exosomes in Therapy: Engineering, Pharmacokinetics and Future Applications
Current Drug Targets Directing Cardiomyogenic Differentiation and Transdifferentiation By Ectopic Gene Expression – Direct Transition Or Reprogramming Detour?
Current Gene Therapy Hyperglycemia-Related Pathophysiologic Mechanisms and Potential Beneficial Actions of Melatonin
Mini-Reviews in Medicinal Chemistry Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Current Pharmaceutical Design Natural Products as a Source of Antiarrhythmic Drugs
Mini-Reviews in Medicinal Chemistry Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry The Concurrent Therapeutic Potential of Adipose-derived Mesenchymal Stem Cells on Gentamycin-induced Hepatorenal Toxicity in Rats
Current Stem Cell Research & Therapy The Role of Autophagy in the Pathogenesis of Ischemic Stroke
Current Neuropharmacology Extra-Hematopoietic Effects of Erythropoietin
Cardiovascular & Hematological Disorders-Drug Targets Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Concepts of Egr-1 Activation – A Hub for Signal Transduction Cascades
Current Signal Transduction Therapy